^
    1d
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710
    1d
    Virtual Rehabilitation for Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=388, Recruiting, University Health Network, Toronto | Trial completion date: Aug 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    1d
    Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) (clinicaltrials.gov)
    P3, N=89, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • 5-fluorouracil • epacadostat (INCB024360)
    1d
    Integrated profiling reveals polarity protein dysregulation during oral cancer progression. (PubMed, Sci Rep)
    The strong concordance between immunohistochemical and transcriptomic profiles-with the exception of DLG7-highlights the disruption of cell polarity as an early and central molecular event in oral carcinogenesis. Collectively, the polarity regulators PAR3, SCRIBBLE, and DLG7 emerge as promising biomarkers for early malignant transformation in oral potentially malignant disorders (OPMDs) and as potential modulators of tumor initiation, progression, and invasive behavior.
    Journal
    |
    PARD3 (Par-3 Family Cell Polarity Regulator)
    1d
    AI-driven multi-omics integration of cancer-associated fibroblasts for prognostic modeling and therapeutic target discovery in head and neck squamous cell carcinoma. (PubMed, NPJ Precis Oncol)
    Furthermore, therapeutic vulnerabilities were explored by integrating drug sensitivity prediction, AI-assisted cMAP screening, and molecular docking validation, which identified Epothilone B as a promising agent targeting HBEGF. Overall, this research shows that understanding the heterogeneity of CAFs with AI-enabled multi-omics modeling can reveal prognostic biomarkers and therapeutic targets for overcoming resistance, with the ultimate goal of improving precision oncology for HNSCC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    patupilone (EPO 906)
    1d
    Myostatin, activin-A and follistatin are produced by the tumor in head and neck cancer and likely contribute to sarcopenia: a case-control, cross-sectional exploratory study. (PubMed, Clin Nutr ESPEN)
    The MAF secretory profile is modified in HNC. In particular, A seems to play a role in muscle loss while F protects against skeletal muscle mass loss.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    1d
    Molecular docking and dynamics reveal CCNB2 as a functional target of lncRNA ADAMTS9-AS1-002 in HNSCC. (PubMed, Biochem Biophys Res Commun)
    These findings indicate a strong interaction between lncRNA ADAMTS9-AS1-002 and CCNB2 expression or function, with a substantial contribution to uncontrolled cell proliferation and oncogenic progression in HPV-positive HNSCC. Furthermore, this study also identifies CCNB2 as a critical downstream effector of ADAMTS9-AS1-002, which can be harnessed as a promising molecular signature for therapeutic intervention in head and neck cancers positive for HPV.
    Journal
    |
    CCNB2 (Cyclin B2)
    2d
    Deciphering the oncogenic role of key genes in HNSC: insights from multi-omics and functional studies. (PubMed, Discov Oncol)
    In conclusion, MAPK3, MLLT4, PLAU, and SERPINE1 emerge as promising biomarkers and therapeutic targets for HNSC.
    Journal
    |
    SERPINE1 (Serpin Family E Member 1) • AFDN (Afadin, Adherens Junction Formation Factor) • MAPK3 (Mitogen-Activated Protein Kinase 3) • PLAU (Plasminogen Activator)
    2d
    Potential anticancer effects of Peganum harmala in human papillomavirus-related cervical and head and neck cancer cells. (PubMed, Front Pharmacol)
    Furthermore, harmine was found to have anti-invasive properties. These findings showed potential harmine antiproliferative and antimetastatic activities, indicating its potential for further research in developing natural therapeutic agents.
    Journal
    |
    CASP3 (Caspase 3) • ANXA5 (Annexin A5)
    2d
    Complex HPV-human DNA structures revealed by large-scale DNA analyses in an HPV-cancer derived cell line. (PubMed, bioRxiv)
    A subset of cells also harbored HPV16 ecDNA derived from the intrachromosomal HPV- TP63 DNAs. These findings define previously unrecognized higher-order architecture of integrated HPV DNA and highlight the power of FISH for distinguishing intrachromosomal from extrachromosomal DNA structures.
    Preclinical • Journal
    |
    TP63 (Tumor protein 63)
    2d
    MULTINECK: Multimodal Prediction of Response to Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P=N/A, N=152, Not yet recruiting, Centre Henri Becquerel
    New trial
    2d
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Recruiting, University of Chicago | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)